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The  immune  response  against  antigenic  determinants  of  immunoglobulin  (Ig) 
molecules  (i.e.,  isotypes,  allotypes,  and  idiotypes)  has  been  extensively  studied.  In 
mice, it has been shown that the antibody response against  allotypic determinants  is 
under Ir gene control (1,  2). 
The study of homologous and autologous anti-Ig responses has suggested that these 
responses  may  be  uniquely  similar  among  genetically  distinct  individuals.  Thus, 
autologous anti-IgG antibodies  in humans  (rheumatoid  factors) show a  considerable 
degree of homogeneity, with many of those studied  bearing a  cross-reactive idiotype 
(IdX) 1 (i.e.,  Wa)  and others bearing other cross-reactive idiotypes (Id)  (3, 4). In mice 
and in rabbits,  it has been shown that anti-allotype antibodies bear cross-reactive Id 
(2,  5,  6),  indicating  that  the  genes encoding the  anti-allotype  immune  response are 
highly conserved. Similarly, syngeneic and homologous anti-Id antibodies share IdX 
in some cases. Because of these findings, the purpose of this investigation was to study 
the Id of the anti-Ig response in a heterologous system (murine/human),  in which the 
immunogen was a  human monoclonal IgM anti-y-globulin bearing the IdX Wa (7). 
Study of the idiotypy of murine anti-human V  region of G1 antibodies produced by 
various strains  of mice has  shown  that  they share  an  IdX,  despite  the  fact  that  the 
fine specificity of these antibodies is different from one strain to another. In addition, 
we found that  A/J anti-Id antibodies  recognize an epitope  related  specificity borne 
by the  Fcy fragment  and  shared  by various  human  IgM monoclonal proteins.  We 
have  called  these  anti-Id  antibodies  epibodies.  Finally,  a  fraction  of anti-anti-Id 
antibodies bound to the antigen and therefore behaved as homobodies. 
* Supported by research grants AG/A10271601A1 and All0811 from the U. S. Public Health Service 
and grant PCM81105788 from the National Science Foundation. 
1 Abbreviations used in this paper:  Abl, anti-epitope antibody;  Ab2, anti-Id  antibody;  Aba, anti-anti-Id 
antibody; Ab4, anti-anti-anti-Id antibody; C region, constant region; epibody, Ab2 antibody that is able to 
recognize similar "structures" or "shapes" borne by epitope and Abe; epitope, antigenic determinant; FCS, 
fetal calf serum; tlA, hemagglutination; HI, hemagglutination inhibition; homobody, Abz antibody that 
mimics the antigen and binds to Abl and cell receptor for the antigen; IdI, individual idiotype; idiotope, 
individual antigen of the idiotype; IdX, cross-reactive idiotype; K, kappa chain; MHC, major histocom- 
patibility complex; RIA, radioimmunoassay; SRBC, sheep erythrocytes; V region, variable region. 
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Materials and Methods 
Mice.  BALB/c,  C.B20,  C58/J,  DBA/2,  A/J,  PL/J,  P/J,  CE/J,  C57BL/6,  and  AKR/J 
mice, 6-8 wk old, were used in this study. 
Human Proteins. IgMKm GI and PG and IgMm Lay with anti-IgG activity and IgMKm Dau, 
Ch, Ga, and Sal with no known specificity were used in this study. They are all monoclonal 
IgM proteins obtained from patients with macroglobulinemia or mixed cryoglohulinemia. IgM 
GI was highly purified from the cryoglobulin of patient G1 by zone electrophoresis as the first 
step followed by G200 chromatography. The final preparation showed no detectable IgG by 
hemagglutination. 
Preparation of Human Ig Fragments.  Fab fragments of IgM GI and PG, Fcy fragments of IgG, 
and Fc/~ fragments of IgM G1 were prepared according to previously described techniques (8). 
Immunization of Mice.  Various strains of mice were immunized intraperitoneally according 
to the method of Tung and  Nisonoff (9) with 0.1  ml of an emulsified mixture of 10 mg/ml 
myeloma protein and complete Freund's adjuvant (1:9 ratio). Ascitic fluid was harvested after 
the fourth immunization. 
Separation of Anti- V Region Gl Antibodies.  An ammonium sulfate fraction of ascitic fluid was 
successively absorbed on Sepharose 4B coated with human IgG and IgMKm Ch columns. The 
effluent was precipitated with ammonium  sulfate, dialyzed, and passed over an IgMKm G1- 
Sepharose 4B column, and antibodies were eluted from this column with glycine-HCl buffer 
(pH 2.8) as previously described (2). 
Preparation of Anti-Id Antibodies.  Anti-V-region G1 antibodies separated from the ascitic fluid 
from single BALB/c mice were coupled with keyhole limpet hemocyanin (KLH), as previously 
described  (2),  and  then  used  as  immunogens  to  prepare syngeneic anti-Id  (anti-V-region) 
antibodies, as previously described (4). Monoclonal anti-anti-VH antibodies were prepared by 
fusion of Sp2/0 myeloma cells with spleen cells from CB6 F1 mice immunized with syngeneic 
affinity-purified anti-Vn  G1  antibody-KLH conjugate.  Hybrids producing  anti-anti-Vn GI 
antibodies detected by  the ELISA technique,  as previously described (10),  were cloned on 
thymocyte filler, and the clones were expanded in pristane-primed CB6 Fx mice. 
Hemagglutination Assay (HA).  HA titers of murine anti-V region G1 or BALB/c anti-(BALB/ 
c anti-V region) antisera were measured in microtiter plates using sheep erythrocytes (SRBC) 
coated with human IgM myeloma protein GI, PG, Ch, Sal, Ga, or BALB/c anti-V region GI 
antibodies, respectively. The proteins were coated onto SRBC using Cr C13 (2).  In each case, 
the titer recorded as 1/log2 of the highest dilution of antisera that caused agglutination. 
Determination of Serum IdX  Titer.  A  hemagglutination  inhibition  (HI)  method  described 
previously  (2)  was  used  to  test  sera  for  IdX.  In  these  experiments,  specifically purified 
BALB/c or P/J anti-V region G1 antibodies were coupled with SRBC. The capacity of various 
sera to inhibit hemagglutination of these cells by BALB/c anti(anti-V region) antibodies was 
determined.  The  titer  reported  as  1/1og2 of the  highest  dilution  that  caused  inhibition of 
hemagglutination. 
Radtoimmunoassay (RIA).  Purified  BALB/c  anti-anti-V  region antibodies and  goat  anti- 
mouse Ig antibodies were labeled with 125I, as described by Hunter (11). 
The ability of anti-V region GI antibodies to bind to various human IgM myeloma proteins 
was determined in microtiter plates that had been incubated for 18 h with 50/~g/ml myeloma 
proteins, followed by three washings in saline. The plates were incubated for 1 h with 50% fetal 
calf serum (FCS) and, after three washings, were incubated for 3 h with mouse anti-V region 
G1 antibodies. After three washings, the microplates were incubated for 3 h with 50 ~1 of 125I- 
g.~ ~ anti-mouse Ig (New England Nuclear, Boston, MA)  (~50,000 cpm/50/~1). After incuba- 
tions, the microplates were washed extensively, and the radioactivity on plates was measured 
in a 7-spectrophotometer. The titer of BALB/c anti-anti-V region GI antibodies was measured 
with the use of microplates that had been incubated with 50/~g/ml purified anti-V region G1 
antibodies. 
ELISA  Technique. Affinity-purified CB6  F1  and  anti-Vn  GI antibodies were  labeled with 
alkaline phosphatase (grade I; Boehinger Mannheim, West Germany), as previously described 
(10).  The  specific  activity  of  labeled  antibodies  was  930  international  units  of  alkaline 
phosphatase per mg of enzyme-antibody conjugate. Labeled anti-VH G1 antibodies were used 
in ELISA to test the reactivity of monoclonal anti-anti-VH GI antibodies as follows: microtiter 988  ANTI-ID1OTYPE  ANTIBODIES,  ttOMOBODIES,  AND  EPIBODIES 
plates (Dynatech Laboratories, Inc., Dynatech Corp., Alexandria, VA) were coated with IgM 
GI  (10/~g/ml) for 18 h at 4°C. After three washings with phosphate-buffered saline containing 
5% Tween, the microplates were incubated for 3 h  at 4°C with labeled anti-VH G1 antibodies 
(5/d/ml). The labeled anti-Vn GI antibodies were preincubated or not during 30 min at 23°C 
with various amounts of unlabeled monoclonal anti-anti-VH GI antibodies before being added 
to the microtiter plates. Finally, the microtiter plates were reiucubated for  1 h  at  37°C with 
p-nitrophenyl phosphate (1  tablet Sigma) in 5 ml of 10%  (wt/vol) diethanolamine buffer (pH 
9.8).  The enzymatic reaction was stopped with 25/~1 of 3 M  NaOH, and the absorbance at 405 
nm was carried out in an ELISA microreader (Dynatech Laboratories, Inc., Dynatech Corp.). 
Results 
Anti- VRegion Gl Antibodies. Anti-V region antibodies were obtained by immunization 
of various strains of mice with IgMKui monoclonal protein G1 displaying IgG-binding 
activity  and  belonging  to  the  human  WaIdX  subgroup.  These  were  purified  by 
elution from an IgM GI-Sepharose 4B column after previous absorption and elution 
on an IgM Ch-Sepharose 4B column. 
The agglutinating activity as well as the binding activity of these antibodies toward 
various human IgM monoclonal proteins was studied initially by HA and RIA assays, 
respectively. The HA assay results depicted in Table I show that antibodies produced 
in various strains of mice not only have a high agglutinating titer for IgM GI and PG 
of the  WaIdX  subgroup,  but  that  these  antibodies,  excepting those  produced  by 
C57BL/6, AKR/J,  and  C58/J,  also  agglutinated  SRBC  coated with  IgMKui  Wa- 
Dau  monoclonal protein. Thus,  in  further studies  (Table II), we  investigated with 
RIA  the  ability  of anti-Vn  G1  antibodies  produced  in  various  strains  of mice  to 
interact  with several IgMKul  monoclonal proteins.  This study was  performed after 
absorption ofanti-V region G1 antibodies on human IgG and polyclonal IgM obtained 
from one individual. 
The results depicted in Tables I  and II indicate that anti-V region GI antibodies 
produced by various strains of mice can be classified into several groups according to 
their specificity, as follows:  (a)  antibodies produced in certain strains  (BALB/c, for 
example) were specific for IdI and IdX of human IgM myeloma protein GI. The titer 
TAnLE  I 
HA  Titer of Anti-Human  V Region Antibodies Produced in  Various Strains of Mice 
Anti-V region GI anti- 
bodies (100 ~g/ml) from 
ttA titer (log 2 units) 
SRBC coated with 
IgMKIII Wa  +  IgMKIII  IgMKIII  IgMKI  IgMKIII 
GI  Wa  + PG  Wa- Dau  Po  ÷ Lay  Wa- Ch 
BALB/c  > 12  6  2  1  0 
DBA/2  > 12  10  2  2  0 
PL/J  7  7  5  0  0 
C.B20  >12  2  4  I  0 
C57BL/6  >12  2  0  0  0 
AKR/J  7  2  0  0  0 
c58/J  8  2  0  5  0 
RIII  10  10  5  0  0 
CE/J  7  6  7  1  0 
p/j  ! 1  10  7  0  0 
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TAnLE II 
Reaction of Anti-V Region Antibodies Produced  by Various Strains of Mice against Different Monoclonal 
IgM Proteins 
Origin of anti-V 
region Gl 
antibodies 
(100/*g/ml) 
IgM GI*  IgM PG*  [gM Dau  IgM Sa  IgM Ga  IgM Ch 
BALB/c  1,643+40  1,174+20  143+23  166+-_29  134+46  42+ 18 
AKR/J  770 ± 27  249 ___ 13  80 + 23  104 + 4  25 + 23  0 
DBA/2  2,641 ± 28  2,079  + 42l  230 + 25  1,242  +- 28  1,420 ± 88  186 _  36 
C.B20  1,395 +  115  543 ± 21  67 -  6  350 ± 27  302 + 9  152 ± 26 
RIII  3,418 ± 36  2,164  ± 294  594 ± 32  521 ± 48  534 ± 44  324 +  103 
PL/J  2,834 ± 43  1,186  ± 32  1,716  ± 293  913 ± 51  510 ± 47  0 
P/J  1,434±  199  893± 105  494±42  562± 105  126±62  105±3 
CE/J  1,935 ± 54  1,236  _  59  1,106  + 24  793 +  76  1,043 ± 50  0 
A/J  2,942±528  2,734±200  2,114±62  2,494± 10  1,824±52  209±52 
*  Anti-y-globulin. 
Counts per minute ± SD. 
Microtiter plates were coated for 18 h at 4°C with 50 #g/ml of various myeloma proteins and washed 
three times and incubated 1 h with 50% FCS. After three washings, they were incubated for 3 h at 4°C 
with anti-V region GI antibodies washed three times and then incubated for 3 h at 4°C with 1251-goat 
anti-mouse antibodies (10,000 cprn). The nonspecific binding to microplates coated with 50% FCS was 
substracted. In the experiment illustrated in this table, the background was  385  +- 52.  Each value 
represents the  average of triplicates. SD  was  calculated on  values after substraction of average of 
background. 
and the specific binding of these antibodies were much higher for IgM G1 than for 
IgM  PG.  PG is  an IgMKin myeloma protein with anti-T-globulin activity that  also 
belongs to  the WaldX subgroup.  (b)  Antibodies produced in other strains (DBA/2 
for example)  were mainly specific for WaIdX because the  HA titers or the specific 
binding activity were roughly equal for GI and PG WaIdX  + monoclonal proteins. (c) 
Antibodies produced in PL/J mice, for example, recognized WaIdX and also frame- 
work  determinants shared  by certain IgM  monoclonal proteins, which  lack anti-y 
globulin activity. 
Id of Anti- V Region  G1 Antibodies.  BALB/c  anti-G1 antibodies that  are  primarily 
specific for WaIdX and Gl IdI were used as immunogens to prepare syngeneic anti-Id 
(i.e., BALB/c anti-BALB/c anti-V region GI antisera). These antisera were compared 
with  BALB/c anti-anti-V region Ch  antibodies, Ch  being an IgM protein without 
anti-y activity. They agglutinated BALB/c  and DBA/2 anti-G1 antibodies at  high 
titers and the control BALB/c anti-V region Ch antibodies at a  very low titer. They 
did  not  interact  with  routine  anti-Id  (i.e.,  A48Id)  or  anti-allotype  (i.e.,  IgGba) 
antibodies (Table III). From these results, we concluded that the syngeneic BALB/c 
anti-anti-V region  G1  antibodies showed  specificity  for  Id  determinants of anti-V 
region GI antibodies. 
In further experiments, we used these syngeneic anti-anti-Id antisera to investigate 
the presence of IdX on anti-V region G1 antibodies produced by various strains of 
mice.  The  results  presented  in  Table  IV  show  that  anti-V  region  GI  antibodies 
produced by various strains of mice share an IdX recognized by BALB/c anti-anti-V 
region GI antibodies. The expression of this IdX is independent of the MHC or the Igh 
gene complex. 
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TABLE  III 
HA Titer of Syngeneic BALB/c Anti-Anti-V Region Gl Antibodies 
SRBC coated with purified 
antibodies 
HA titer (log2 units) 
Agglutinating antisera 
BALB/c anti-  BALB/c anti- 
anti-V region  anti-V region 
(GI)  (Ch) 
BALB/c anti-V region GI  8  1 
BALB/c anti-V region Chr  0  5 
DBA/2 anti-V region GI  >8  0 
RIII anti-V region G1  3  0 
BALB/~  anti-A48Id*  0  0 
BALB/c anti IgG~, allotype~  0  0 
* ABPC48  is  murine IgAk fl2-6 fructosan-binding myeloma protein  that  ex- 
presses A48Id shared with UPC10 myeloma protein. 
:t:These  antibodies  were  obtained  by  immunization of BALB/c  mice  with 
CBPC  101  myeloma protein  and  purified  on  Sepharose  4B-C57BL/6  Ig 
columns, 
TABLE  IV 
Expression of Cross-Reactive Id of BALB/c Anti-V Region Gl Antibodies in Various Strains of Mice 
ttl titer (log2 
units)~ of IdX 
antibodies  Number of 
mice ex-  Anti-V region GI  H2  IghC 
antibodies from*  pressing 
ldX 
BALB/c  P/J 
RIA 
125I BALB/c anti(anti-V 
region GI antibodies +  mi- 
croplates coated with anti- 
V  region antibodies 
BALB/c  d  a  9  9  8/11  5,467 +  12l 
DBA/2  d  c  8  5  2/4  4,629 +  70 
PL/J  u  .1  4  4  2/4  3,422 +  283 
C.B20  d  b  8  2  2/4  3,840 ±  417 
C57BL/6  b  b  8  5  4/4  4,203 +  60 
AKR/J  k  d  9  6  3/4  3,784 +  720 
C58/J  k  a  3  5  5/5  2,896 +  707 
RIII  r  g  3  5  4/4  1,134  +  351 
P/J  p  h  6  8  2/4  4,417 +  603 
CE/J  k  q  2  2  2/6  1,704  +  12 
A/,J  a  e  0  0  0/6  380 +  88 
Anti-A48Id(BALB/c)  d  a  0  0  --  197 +  21 
* In HI assay, the purified anti-V region GI antibodies enumerated in column  1 were used as inhibitors, 
whereas in RIA they were used to coat the microtiter plates (at 50 ~g/ml concentration), 
:~ Two systems were used to investigate the expression of IdX on anti-V region Gl antibodies as follows: 
BALB/c anti-anti-V region GI antiserum and SRBC§ coated with BALB/c anti-V region GI or 
P/J anti-V region GI antibodies. 
interstrain  IdX.  It  should  be  mentioned  that  this  IdX  was  not  identified  on  two 
murine  monoclonal  antibodies  specific  for  the  human  ~  chain,  kindly  provided  by J. 
Kearney,  University  of Alabama,  for  this study. 
Polyclonal Syngeneic Anti-Anti- V Region Gl Antibodies  Contain a Subset  That Binds to Human 
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antibodies to  bind  to  the  human  Fcy fragment.  The  rationale of this  investigation 
follows from several reports that suggest that anti-Id antibodies represent the internal 
image of antigen and from the fact that human IgM with anti-y globulin activity was 
the initiator of the anti-anti-V region G1 antibody pathway. A  comparative study of 
the binding of these anti-anti-V region Gl antibodies to plates coated  with  various 
human  IgM  myeloma  proteins  and  Fc),  fragments  demonstrated  that  a  subset 
representing  ~  10%  of this population of antibodies bound  to Fc. This  binding was 
inhibited by preabsorption of anti-anti-V region GI antibodies with the FcT fragment 
but  not with  the Fab GI fragment.  No binding of heterogeneous 3H-syngeneic anti- 
anti-A48Id antibodies to Fc), fragments was observed in control experiments  (Table 
V). These results suggest that a  fraction of syngeneic (BALB/c) anti-anti-V region Gl 
antibodies  displayed a  binding  activity similar  to  IgM  GI,  the  anti-), monoclonal 
protein that was the initiator of this network pathway.  In these terms, this subset of 
antibodies that bind to Fcy fragments can be considered as homobodies (12). 
Monoclonal Syngeneic Anti-Anti- V Region Gl Antibody That Bind to Human IgM Monoclonal 
Proteins.  Several  syngeneic  CB6/Fa  monoclonal  anti-anti-V  region  GI  antibodies 
were obtained by fusion of SP2/0 myeloma cells with spleen cells from CB6/F1 mice 
immunized with anti-V region G1 antibodies. The majority of these monoclonal anti- 
anti-V  region  antibodies  bound  labeled  anti-V  region  G1  antibodies  as  well  as 
inhibited the binding of anti-V region G1 antibody to IgM GI monoclonal protein. 
Among these monoclonal anti-anti-V region antibodies, we found one, P 1A2.3, that 
did not bind labeled anti-V region G1 antibodies but was able to inhibit the binding 
of anti-V region GI antibodies to IgM GI monoclonal protein (Table VI). Surprisingly, 
we found that this monoclonal antibody significantly bound to IgM GI, PG, Sal, and 
Ga  (IgMKni),  but  not  to  IgM  Dau,  Ch  (IgMKm),  Lay  (IgMK1),  and  human  IgG 
(Table  VII).  The  binding  of P1A2.3  monoclonal  antibody  to  human  monoclonal 
proteins GI and Ga was inhibited with Fab G1 and Fab PG, but not with Fc/~ Gl (Fig. 
TABLE g 
Binding of BALB/C Anti (BALB/C Anti- V Region (Gl) Antibodies to 
Human Fc Fragment 
Plates coated with  Absorption  125I-BALB/c  of anti-  anti-anti-V  3H-BALB/C anti- 
50/tg/m of  bodies  region  anti-A48Id* 
BALB/c anti-V region GI  --  5,467 +  121'  332 ± 25* 
BALB/c anti-V region Ch  --  196 +  10  356 +  18 
BALB/c anti-A481d  --  197 ± 2l  14,685 ± 2,135 
IgM Wa  ÷ GI  --  289 ±  112  342 ± 24 
IgM Wa  ÷ PG  --  342 ± 65  333 __. 24 
IgM Po  + Lay  --  153 ± 42  342 ± 35 
IgM Wa- Da  --  220 ± 63  335 ± 26 
Human IgG  --  484 ±  112  305 4- 38 
FcT  --  651 ± 38  336 ± 28 
Fey  Fab GI  §  648 ± 26  388 +  122 
FcT  Fcy  ~  305 ±  18  312 ±  16 
FCS (50%)  --  328 ± 33  289 + 22 
* This antibody used  as a  control  is specific for the A48 Id of murine  ABPC48 
monoclonal protein (IgA kappa with B2-6 fructosan-binding activity). 
t 50 #g/ml. 
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TABLE  VI 
Binding and Inhibitory Activity  of Two Monoclonal Anti-Anti- V Region Gl 
Antibodies  (ELISA ) 
VIA Binding Activity 
Microtiter plates coated with  Binding of labeled anti-V region 
antibodies (5/~g/ml)* 
BSA  0 
IgM (GI)  0.52:1: 
IgM (PG)  0.15 
PIA5.6  0.16 
PIA2.3  0.02 
Microtiter  plates were coated  for  18  h  with proteins mentioned in column  l 
and then incubated with alkaline phosphatase-labeled anti-V region GI anti- 
bodies. 
VIB Inhibitory Activity 
Inhibitors  Binding of labeled anti-V region 
antibodies* 
Nil  0.27~: 
IgM (GI)  0 
IgM (PG)  0.13 
PIA5,6  0,06 
PIA2.3  0.08 
Microtiter  plates were coated  with  IgM GI  50  bLg/ml, and  labeled  anti-V 
region antibodies were preincubated for  1 h  at 23°C with inhibitors before 
being incubated in microtiter plates. 
* Alkaline phosphatase-labeled CB6 F1 anti-V region Gl antibodies. 
* OD, 405 nm 
TABLE  VII 
Binding of P1A2.3 Monoclonal Anti-Anti- V Region Gl Antibody to  Various Human IgM Monoclonal 
Proteins 
Binding of 
Microtiter plates 
coated with  BALB/c anti-  CB6 F1 anti-V  P1A2.3  P4D2.7 
human Ig  region GI 
IgM Gl  18,392 +  1,184"  12,575 +  2,600  6,059  +  799  1,544 +  1,146 
IgM PG  20,236  +  2,819  11,792 +  3,191  11,068 +  18  252 +  257 
IgM Dau  23,586  +- 989  2,898 +  1,782  1,678 +  373  2,363  +  408 
IgM Sal  16,639 -+  1,629  403 +  385  6,610  +  193  0 
IgM Ga  16,957 +  57  681  +  635  2,744  +  470  0 
IgM Lay  12,926 +_ 870  1,088 +  202  0  0 
IgM Ch  18,645 -+  1,058  85 +  43  905 +  147  115 +  16 
IgG  18,046 +  521  354 +  300  959  +__ 958  0 
Microtiter plates were coated with 50 p.g/ml of human IgM monoclonal proteins mentioned in column 
I and then with 50 #g/ml of purified heterogeneous BALB/c anti-human Ig or CB6 Fi anti-V region G1 
antibodies or with P1A2.3  or P4D2.7  monoclonal CB6 Fl anti-anti-V region GI antibody. Their binding 
was estimated in RIA by incubating the plates with 50,000  cpm lzSI-goat anti-mouse Ig. The binding is 
expressed as mean +  SD of cpm after the subtraction of the background (i.e., the binding 125I-goat anti- 
mouse Ig to human IgM proteins). 
* Results expressed as cpm minus mean of triplicates +  SD. C.  A.  BONA,  S.  FINLEY,  S.  WATERS,  AND  H.  G.  KUNKEL  993 
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Fio.  l.  Inhibition of binding of PIA2.3 monoclonal antibody to human IgM Gl by IgM fragments. 
Microtiter plates were coated with human IgM GI (50 #g/ml) overnight, washed three times, and 
then incubated for 1 h with 50% FCS. PIA2.3 was preincubated for 1 h with human IgM fragments 
and then added for 3 h to IgM Gl-coated plates. After three washings, the microplate was incubated 
for 3 h with ~2Sl-goat anti-mouse antibody, washed extensively, and radioactivity was counted in a 
y-spectrometer.  O, Fab GL; A, Fab PG; 0, Fcp.  GL. 
1).  It should be mentioned that  50% inhibition was reached with high amounts of 
Fab fragments (100 #g/ml). This particular monoclonal anti-anti-V region G1 anti- 
body, which interacts with anti-V region antibodies as well as with antigenic deter- 
minants of V  region Gl, which we have called epibodies. 
Special Properties  of A/J Anti-V Region Gl Antibodies.  Special studies were carried out 
on A/J anti-V region Gl antibodies. These antibodies, obtained by the same regimen 
of immunization  used  for other strains,  exhibited two peculiar properties:  (a)  they 
bound in an equal manner to most IgM myeloma proteins independent of anti-IgG 
activity (Table II); and (b) they did not express the IdX recognized by BALB/c anti- 
anti-V region G1 antibodies. 
Because  of these  particular  properties  of A/J  anti-V  region  Gl  antibodies,  we 
studied their binding to human IgG. The data presented in Table VIII showed that 
anti-V region Gl antibodies produced in A/J mice, but not in other strains, exhibited 
the ability to bind to human  IgG. In further experiments, we studied the effects of 
absorption of A/J  anti-V region G1 antibodies with  various IgM proteins, Fab Gl, 
Fc),, and IgG on their ability to agglutinate IgM G1-SRBC or to bind to microtiter 
plates coated with Fc), fragment. The results presented in Table IX showed that the 
ability of A/J anti-V region antibodies to agglutinate SRBC was partially inhibited 
after absorption with IgM Gl, Sal, Dau, Fab G1 fragments, IgG, and Fc), fragments. 
Similarly, the binding of these antibodies to Fc), fragments was inhibited by the same 
proteins.  We  explain  these  results  by  a  possible  related  epitope  between  the  Fc), 
fragment (for which the IgM G1 is specific) and  framework determinants of various 
other IgM proteins. Therefore, these anti-Id antibodies that bind to the V  region of 
human IgM proteins and to the Fc), fragment can also be considered epibodies. 
Discussion 
The results presented in this communication indicate that various strains of mice, 
in  response  to  immunization  with  a  rnonoclonal human  IgM  protein  with  anti-), 994  ANTI IDIOTYPE  ANTIBODIES,  HOMOBODIES,  AND  EPIBODIES 
TABLE  VIII 
Binding of anti- V Region Gl Antibodies Produced  in  Various Strains of Mice 
to Human IgG 
Antibodies  cpm 
Nil 
BALB/c anti-human Ig 
BALB/c anti-V region Ch 
BALB/c anti-V region GI 
DBA/2 anti-V region GI 
RIII anti-V region GI 
P/5 anti-V region GI 
A/J anti-V region GI 
C.B20 anti-V region Gl 
PL/J anti-V region GI 
C58/J anti-V region GI 
AKR/J anti-V region GI 
CE/J anti-V region GI 
3,536 +  349 
22,959 4- 521 
3,673 4- 519 
3,826 4- 471 
5,050 4- 318 
6,353 +  545 
4,57O 4- 533 
17,340 4-  1,463 
3,412 4- 240 
8,732 +  316 
2,721  4- 528 
1,665 +  203 
5,446 +  164 
Microtiter  plates were  coated  for  18  h  at  4°C  with  50 /~g/ml  human IgM, 
washed three times, and incubated for  1 h with 50% FCS, washed three times 
and then coated with 50/Lg/ml antibodies mentioned in column 1. After three 
washings,  the  plates  were  incubated  for  3  h  at  4°C  with  50,000  cpm  of 
12~I-goat anti-mouse Ig. Results are expressed in cpm mean 4- S.D. 
TABLE  IX 
Absorption of Human Fc-Binding Activity of A/J Anti-V Region Gl 
Antibodies 
Absorption of A/J anti-V  HA(log2 units) 
region G1 antibodies with*  titer*  RIA (cpm):~ 
None  7  8,897 +  23 
Fab Gl  2  6,667 -  342 
Fc  4  5,669 -  156 
IgG  3  4,467 4-  156 
Polyclonal IgM  6  7,128 +  525 
IgM Wa  ÷ GI  3  6,380 4- 394 
IgM Wa- Sal  5  5,836 4-  144 
IgM Wa  Ga  7  8,587 4- 488 
IgMWa-Dau  5  6,117+  1 
IgM Wa- Ch  7  8,767 4- 460 
IgM Po + Lay  7  8,839 "4- 485 
* SRBC coated with IgM GI. 
~: Microplates coated  for  18 h  with  Fcy  (30 /lg/ml)  washed three times and 
then incubated further with 50% FCS. After three washings, the microp[ates 
were incubated for 3 h  with A/J anti-V antibodies washed three times and 
the  incubated  for  3  h  with  J25I-goat  anti-mouse  antibodies.  Results  are 
expressed in cpm, mean of triplicates +  SD. Adsorption was performed by 
mixing  equal  volumes  (i.e.,  100  /~g/ml)  of anti-A/J  anti-V  region  (GI) 
antibodies  and  various  proteins  for  30  rain  at  room  temperature  before 
incubation in RIA or use in HA assays. 
globulin  activity  and  bearing  the  WaIdX,  produced  multiple  antibodies  with  specif- 
ities for IdI,  WaIdX,  and  against  framework-associated  antigenic  determinants  of the 
monoclonal  protein  used  as the  immunogen. 
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IdX. The expression of this IdX is independent of the MHC or Igh gene complexes. 
This  suggests  that  the  response  to  idiotypic determinants  of antibodies  produced 
across heterologous as well as homologous (2,  5, 6)  and syngeneic (3,  13)  barriers is 
highly conserved. The existence of an interstrain IdX that is expressed in the majority 
of the individuals of several strains strongly suggests that this response is encoded by 
a germ line gene. 
The  study  of the  binding  activity  of anti-V  region  and  anti-anti-V  region  G1 
antibodies, obtained by hetero or syngeneic immunization, respectively, showed that 
some  of these  antibodies  display  special  binding  activity. Thus,  we  found  that  a 
fraction  of anti-anti-V  region  G1  antibodies  exhibited  antigenic-binding  activity 
similar  to  the  IgM  G1  monoclonal  protein  that  was  the  initiator  of our  network 
pathway. These antibodies, which represent  -10% of total anti-anti-V  region anti- 
bodies, bound to Fcy and can be considered homobodies, as defined previously (12). 
In  our  system,  Abl,  i.e.,  human  IgM  monoclonal  protein  with  anti-y  globulin 
activity, recognizes epitopes of the  Fcy fragment.  Immunization  of mice with  Aba 
induces the synthesis of anti-V region antibodies, which can be considered as Ab2 or 
anti-Id  antibody.  Some  idiotopes  of the  Ab2  antibodies  are  probably  similar  to 
epitope(s) of the Fcy fragment and represent their internal image. Therefore, immu- 
nization of a second mouse with these anti-V region antibodies elicited the production 
of a  family of anti-anti-V region antibodies; among these, a  small subset recognizes 
some epitopes of the Fcy fragment as well as  the  idiotopes of Ab2 antibodies.  The 
existence of these homobodies implies, first, a certain degree of similarity of structure 
between  the  antigen  and  anti-V  region  antibodies  and,  second,  that  some anti-Id 
antibodies represent the "internal image" of the antigen within the immune system. 
A prediction of the internal image concept is that homobodies might bind to antigen, 
displacing  Abl,  because  the  same  interaction  takes  place  between  antibody  and 
antigen as between homobodies and antigen. 
There are several examples that  suggest that  homobodies represent topochemical 
copies of the antigen. Thus, Ab4 (i.e., anti-anti-anti-Id antibodies), obtained in rabbits 
and in mice in the M.  lysodeikticus or bacterial levan systems, display binding activity 
similar to Ab2 (i.e., anti-Id antibodies) to idiotypic determinants of Abl (14, 15). If the 
idiotopes of Abl are considered as epitopes in these systems, then Ab4 represents the 
internal image of the Ab2-combining site, because Aba and Aba share similar idiotopes. 
The  internal  image  concept  predicts  that  homobodies  can  display  biological 
functions of the antigen. Sege and Peterson (16)  have shown that anti-Id antibodies 
against  anti-insulin antibodies can mimic some functions of insulin. Schreiber et al. 
(17)  found that anti-Id antibodies against  rabbit anti-alprenelol antibodies compete 
with  the binding of dehydroalprenelol to/~-adrenergic receptors and  can stimulate 
basal adenylate cyclase activity in the cells bearing these receptors. 
A  second category of antibodies observed in our system was  quite different and 
exhibited the ability to bind to both the epitopes of the antigen and idiotopes of the 
antibodies. We found two types of antibodies that exhibited this peculiar property as 
follows: (a) a monoclonal anti-anti-V region antibody (Ab3) that binds to IgM G1 as 
well as several IgM proteins. This binding was inhibited by Fab GI and PG fragments 
but  not  by Fc~ G1 fragments;  and  (b)  a  polyclonal A/J anti-V region GI antibody 
(Ab2) that was able to recognize some epitopes of Fcy fragments as well as framework 
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The (a) type of antibody was a clear-cut reaction of a  monoclonal antibody from a 
mouse that  had not  received human  Ig, but where the anti-anti-V region  antibody 
reacted with the human IgM. The (b)  type antibody might conceivably have arisen 
because the original IgM GI used to give rise to anti-V region antibodies, despite its 
known purity, was contaminated with small amounts of [gG that produced anti-IgG 
antibodies. A number of observations argue against this possibility: (a) the reaction of 
the antiserum with IgM GI was markedly reduced by absorption with IgG that could 
only have been the case if there was a large contamination of IgM G1 with IgG. This 
is known not to be the case (b) The reaction of A/J anti-V region GI antibodies with 
IgM GI was virtually lost by absorption with the Fab fragment of IgM Gi.  (c)  None 
of the other mouse strains produced such antibodies when injected with IgM GI, 
The best explanation of the peculiar binding activities of these antibodies  is that 
they recognize some idiotopes or framework determinants of anti-Id antibodies that 
mimic the shape of the epitopes of the immunizing antigen, which was the initiator 
of the idiotypic network pathway. We have called these epibodies.  Fig.  2 shows the 
various antibodies studied and the specific reactions of the two types of epibodies. 
One may speculate about  the structural  homology and cellular mechanisms that 
lead to the occurrence ofepibodies. There are few data on the 3-dimensional structures 
of V  domains of an antibody molecule that allow it to recognize epitopes and to be 
recognized by an antibody that  generally is defined as an anti-Id antibody (18,  19). 
There is little knowledge of structural correlates of internal image. 
However, from our study, it clearly appears that the mice immunized with a human 
IgM respond to several epitopes, such as individual  antigenic specificities borne by 
IgM G1  (IdI), WaIdX,  and  framework determinants  of IgM V  regions.  Therefore, 
among the  B  cells  of these  mice,  it  is  possible  that  there  are  clones  that  bear  an 
"idiotype"  that  represents  the  internal  image  of  one  of  the  epitopes  and  that, 
subsequent to the binding to IgM G1, can be stimulated to produce antibody that will 
recognize  the  epitope.  This  explanation  is  supported  by  the  data  regarding  the 
properties of monoclonal anti-anti-V  region G1 antibodies  (Ab3), which  can inhibit 
the  binding-V  region  antibodies  (Ab2)  to  IgM  GI  (Abl),  but  that  has  a  very  low 
binding activity to Ab2, as assessed in ELISA. Therefore, the epibodies appear to be 
combining site-induced  antibodies,  rather than  classical  anti-Id antibodies  induced 
by Id. The epitopes recognized by epibodies probably do not include  the dominant 
epitope that induces the synthesis of Abl, and may represent bystander epitopes that 
resemble idiotopes or framework antigenic  determinants  of a  subset(s)  of Abl  anti- 
bodies (i.e., of human IgM G1 monoclonal protein). 
(anti-y globulin  GI) 
Abl 
t --,.~  -  ~  ~  epibOdy reactiOns 
(Fc) Ag .  ~b2  (anti-ld) 
Ab3 
(anti, anti-ld) 
Fro.  2.  Diagram  showing the series  of antibodies studied and their specific  interactions. The arrows 
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Wordfang  and  Rubin  (20)  reported  some  results  that  can  be  interpreted  as 
epibodies.  They  prepared  in  tolerized  rabbits  a  highly  specific anti-Id  antiserum 
against  B6 anti-CBA  (Ia  K)  antibodies  called  5936  Id.  The anti-5936  Id  antiserum 
binds not  only to B6 anti-Ia  K cytotoxic antibodies,  but  also  to antibody devoid of 
cytotoxic activity. Among various explanations provided by the authors, one that they 
take  into  account  is  that  5936  Id-bearing  antibodies  that  lack  anti-Ia  K cytotoxic 
activity may represent  anti-(anti-CBA)  antibodies that  share 5936  Id with B6 and 
CBA antibodies. 
These data, when considered collectively, indicate that anti-Id antibodies represent 
a  heterogeneous population composed of at least  four major categories:  (a) conven- 
tional  anti-Id  antibodies,  directed against  idiotopes associated  with  the combining 
site (hapten inhibitable);  (b) anti-Id antibodies directed against  idiotopes associated 
with  the  framework of the  V  region  (not  inhibited  by hapten);  (c)  epibodies that 
interact  with  epitope  or  idiotope-related  structures  of antibodies  (Abl)  or  anti-Id 
antibodies (Ab2), respectively; and (d) homobodies that may mimic the antigen (Ab2 
homobodies). 
The existence of epibodies and  homobodies strongly supports  the concept of an 
internal image of the antigen within the immune system (21). This concept, wherein 
the average of the three-dimensional shapes of all V  domains could be cross-reactive 
to the average shapes of epitopes, is significant for the understanding of the genetic, 
regulatory, and recognition mechanisms of the immune system. The implications of 
this  concept  include:  (a)  each  antibody  molecule  can  be  regarded  as  an  anti-Id 
antibody  for another Ig;  (b)  the  immune  system  does  not  consist  of two separate 
entities (anti-epitope and anti-idiotope antibodies), as has been proposed (21), but a 
unitary system of multiple antibodies;  and  (c) that  the antigens are not completely 
foreign because  the  immune  system  already  contains  structures  (i.e.,  Id)  that  are 
similar to the antigens (epitopes). 
Research in progress is designed to test this concept by studying the binding activity 
of several monoclonal anti-murine Id antibodies to human myeloma proteins as well 
as of murine anti-V region G1 antibodies to murine myeloma proteins. 
Summary 
Murine anti-V region antibodies against a human monoclonal protein G1 with anti- 
T-globulin  activity  and  bearing  the  Wa  cross-reactive  idiotype  were  prepared  in 
several strains of mice. Antibodies were obtained that were specific for the GI idiotype, 
the  Wa  cross-reactive idiotype, and  for various  framework antigenic  determinants 
that were distinguished by a variety of procedures. Synthesis of such antibodies were 
found  to  be  independent  of MHC and  Igh  gene  complexes.  These  anti-V  region 
antibodies, produced by a  majority of mouse strains investigated, also share a cross- 
reactive idiotype recognized by BALB/c anti-anti-V region G1 antibodies. A fraction 
of BALB/c anti-anti-V region GI antibodies displayed human  Fc  T binding activity 
and, therefore, can be considered homobodies, as described in other systems. 
Two of the anti-idiotype antibodies obtained  in  this system exhibited a  peculiar 
property: they interacted not only with their own antigen (IgM GI), but also with the 
Fc fragment with which IgM GI reacts. Thus, A/J anti-V region G1 antibodies bind 
to the human Fcy fragment in addition to IgM GI. Similarly, a monoclonal CB6 F1 
anti-anti-V region Gl antibody interacted with the V region of IgM GI as well as with 998  ANTI-IDIOTYPE ANTIBODIES,  HOMOBODIES,  AND  EPIBODIES 
the  syngeneic  anti-V  region  antibodies.  We  called  these  anti-idiotypic antibodies 
epibodies because they interact with  epitopes of the primary antigen.  These  homo- 
bodies and epibodies, obtained by immunization across heterologous barriers, repre- 
sent  new  examples  of recognition  of the  internal  image  of the  antigen  within  the 
immune system. 
Received  for publication 22June 1982. 
References 
1.  Lieberman, R., and W. Humphrey.  1972. Association of H-2 types with genetic control of 
immune responsiveness to IgA allotype in mouse. Proc. Natl.  Acad. Sci. U. S. A. 68:2510. 
2.  Bona,  C.,  P.  K.  A. Mongini, K.  E.  Stein, and W.  E.  Paul.  1980. Anti-immunoglobulin 
antibodies. I. Expression of cross-reactive idiotypes and Ir gene control of the response to 
IgG2a of the b allotype.J. Exp. Med.  151:1334. 
3.  Kunkel, H. G., V. Agnello, F. G. Joslin, R. J. Winchester, and J. D. Capra.  1973. Cross- 
idiotypic specificity among monoclonal IgM protein with anti-y-globulin activity. J.  Exp. 
Med.  137:331. 
4.  Agnello, V., A. Arbetter, I., DeKasap, R. Powell, E. Tan, and J. Joslin. 1980. Evidence for 
a subset of rheumatoid factors that cross-react with DNA-histone and have a distinct cross- 
idiotype.J. Exp. Med.  151:1514. 
5.  Roland, J.,  and  P. A. Cazenave.  1979. Mise en evidence d'idiotypes anti-b4 apparentes 
chez  les  lapins de phenotype a3 + immunis~s contre  l'allotype b4.  C.  R.  Acad. Sci. Paris. 
288:571. 
6.  Gilman-Sachs, A., S.  Dray, and  W. J.  Horng.  1980. A  common  idiotypic specificity of 
rabbit antibodies to the a2 allotype of the immunoglobulin heavy chain variable region.J. 
Immunol. 125:96. 
7.  Kunkel, H. G., R. J.  Winchester, F. G. Joslin, and J.  D. Capra.  1974. Similarities in the 
light chains of anti-y-globulins showing cross-reactive specificities.J. Exp. Med.  149:128. 
8.  Nisonoff, A., F. C. Wissler, and L. N. Lipman. 1960. Properties of the major componenl of 
a peptic digest of rabbit antibody. Science (Wash. D. C.).  132:1770. 
9.  Tung,  A. S.,  S.  T. Ju,  S.  Sato, and  A.  Nisonoff.  1976. Production of large amounts  of 
antibodies in individual mice.J. Immunol. 116:676. 
10.  Hiernaux, J., and C. Bona.  1982. Shared idiotypes among monoclonal antibodies specific 
for  different  immunodominant  sugars  of lipopolysaccharide of different  gram  negative 
bacteria. Proc. Natl.  Acad. Sci. U. S. A. 79:1616. 
11.  Hunter, R.  1970. Standardization of the chloramine-T method of protein iodination. Proc. 
Soc. Exp.  Biol. Med.  133:986. 
12.  Lindemann, J.  1979. Homobodies: do they exist. Ann. d'lrnrnunol. (Inst.  Pasteur).  130C:313. 
13.  Bona, C., and J. Kearney. 1981. Anti-immunoglobulin antibodies It. Expression of individ- 
ual and cross-reactive idiotypes on syngeneic and homologous anti-idiotype antibodies. J. 
Immunol.  127:491. 
14.  Wikler, M., J.  D. Franssen, C. Collignon, O.  Leo, B. Mariame, P. Van de Walle, D.  De 
Groote, andJ. Urbain. I979. Idiotypic regulation of the immune system. Common idiotypic 
specificities between idiotypes and antibodies raised anti-idiotypic antibodies in rabbits.J. 
Exp. Med.  150:184. 
15.  Bona,  C.,  E.  Heber-Katz,  and  W.  E.  Paul.  1981. Idiotypic-antiidiotype regulation.  I. 
Immunization with a levan binding myeloma protein leads to the appearance of auto-anti- 
(anti idiotypic) antibodies and to the activation of silent clones. J. Exp. Med.  153:951. 
16.  Sege, K., and P. A. Peterson.  1978. Use of anti-idiotypic antibodies as cell-surface receptor 
probes. Proc. Natl.  Acad. Sci. ~( S. A. 75:2443. C.  A.  BONA, S.  FINLEY, S.  WATERS, AND H.  G.  KUNKEL  999 
17.  Schreiber, B. A., P. O. Courand, C. Andre, B. Wray, and A. D. Strosberg. Anti-alprenelol 
anti-idiotypic antibodies bind to  fl-adrenergic receptors  and  modulate catecholamine- 
sensitive adenylate eyclase. Proc. Natl. Acad. Sci. U. S. A.  77:7. 
18.  Clevinger, B., J.  Schilling, L.  Hood, and J.  Davie.  1980. Structural correlates of cross- 
reactive and individual idiotypic determinants on murine antibodies to a  1 ~  3 dextran. 
J. Exp. Med. 151:1009. 
19.  Pawlita, M., E. Mushinski, R. J. Feldman, and M. Potter.  1981. A monoclonal antibody 
that defines an idiotope with two subsites in galactan-binding myeloma proteins. J.  Exp. 
Med. 154:1946. 
20.  Nordfang,  D.,  and  B.  Rubin.  1981. Idiotypic regulation of mouse  anti-H-2 antibody 
response I Induction of 5936-idiotype bearing Ig molecules upon immunization with H-2  k 
alloantigen. Immunogenetics. 12:197. 
21.  Jerne, N. K.  1976. The immune system a web of V-domains. Harvey Lectures Academic 
Press, Inc. New York. 70:93. 